satralizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5409 1535963-91-7

Description:

MoleculeDescription

Molfile

Synonyms:

  • satralizumab
  • satralizumab-mwge
  • enspryng
  • SA237
  • SA-237
  • RG-6168
Satralizumab-mwge is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody based on a human IgG2 framework. It is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients. The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 24, 2021 EMA Roche Registration GmbH
Aug. 14, 2020 FDA GENENTECH
June 29, 2020 PMDA Chugai Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC19 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Neuromyelitis optica indication 25044007 DOID:8869
Tuberculosis contraindication 56717001
Viral hepatitis type B contraindication 66071002 DOID:2043




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-6 receptor Membrane receptor ANTAGONIST Kd 8.82 DRUG LABEL DRUG LABEL

External reference:

IDSource
D11079 KEGG_DRUG
YB18NF020M UNII
C4726732 UMLSCUI
CHEMBL3833307 ChEMBL_ID
DB15762 DRUGBANK_ID
9093 IUPHAR_LIGAND_ID
2391541 RXNORM
337831 MMSL
38756 MMSL
d09618 MMSL
897234001 SNOMEDCT_US
897291006 SNOMEDCT_US
4039644 VANDF
4039645 VANDF
018474 NDDF
C000655944 MESH_SUPPLEMENTAL_RECORD_UI
10065 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Enspryng HUMAN PRESCRIPTION DRUG LABEL 1 50242-007 INJECTION, SOLUTION 120 mg SUBCUTANEOUS BLA 28 sections
Enspryng HUMAN PRESCRIPTION DRUG LABEL 1 50242-007 INJECTION, SOLUTION 120 mg SUBCUTANEOUS BLA 28 sections